Scans and blood tests after treatment for cervical cancer
Tests a PET scan and blood HPV checks in people with cervical cancer.
Plain-language title generated from the registry record
Registry title: FDG-PET and Circulating HPV in Patients With Cervical Cancer Treated With Definitive Chemoradiation (II)
Key facts
- Where
- Toronto, CanadaSee the site
Where in Canada
- University Health Network, The Princess MargaretToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Health Network, Toronto
- Trial code
- NCT03853915
- Record updated
- 5 March 2026
- Original description
Nearly all cervical cancers are caused by the human papilloma virus (HPV), which can be detected in cancer tissue by laboratory tests. There is evidence that the virus can also be detected from a blood sample to monitor the effects of treatment. Previous studies have shown that a special test called 18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET-CT) at 3 months after treatment may predict survival in cervical cancer.Read full original descriptionShow less
FDG-PET and Circulating HPV in Patients With Cervical Cancer Treated With Definitive Chemoradiation (II)
Nearly all cervical cancers are caused by the human papilloma virus (HPV), which can be detected in cancer tissue by laboratory tests. There is evidence that the virus can also be detected from a blood sample to monitor the effects of treatment. Previous studies have shown that a special test called 18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET-CT) at 3 months after treatment may predict survival in cervical cancer.
The purpose of this study is to see how well the FDG-PET Scan and blood tests for HPV can detect leftover cervical cancer cells after treatment. This study is not a particular form of treatment and patients will receive standard of care treatment.
Inclusion: Histologically confirmed squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix, FIGO stage IB-IVA; 3.1.2 Planned for radical radiotherapy and concurrent cisplatin chemotherapy; 3.1.3 Age ≥ 18 years.
Exclusion: Evidence of distant metastases (suspicious paraaortic nodes below the renal vessels allowed if they will be encompassed within the radiation field); Patients who have received any anticancer treatment for their cervical cancer; Other cervical cancer tumor histologies (e.g. small cell, serous); Contraindication to radiotherapy (e.g. severe Crohn's disease); Contraindication to chemotherapy (e.g. non-reversible renal failure); History of another invasive malignancy, except for non-melanoma skin cancer or tumors curatively treated with no evidence of disease for ≥ 5 years; Contraindications to 18FDG PET-CT; Known pregnancy or lactating.